Ofir Elalouf1, Anastasiya Muntyanu2, Ari Polachek3, Daniel Pereira2, Justine Y Ye2, Ker-Ai Lee4, Vinod Chandran5, Richard J Cook4, Dafna D Gladman6. 1. Centre for Prognostic Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Toronto, ON Canada; Department of Rheumatology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 2. Centre for Prognostic Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Toronto, ON Canada. 3. Department of Rheumatology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 4. Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON Canada. 5. Centre for Prognostic Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Toronto, ON Canada; Departments of Medicine, Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON Canada; Institute of Medical Science, University of Toronto, Toronto, ON Canada. 6. Centre for Prognostic Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Toronto, ON Canada; Institute of Medical Science, University of Toronto, Toronto, ON Canada. Electronic address: dafna.gladman@utoronto.ca.
Abstract
BACKGROUND/ OBJECTIVES: Mortality studies in psoriatic arthritis (PsA) have provided inconsistent results. This study aimed to: 1) Estimate trends in mortality rates among PsA patients over calendar time; 2) Evaluate cause-specific mortality rates in patients with PsA compared to the general population; 3) Identify predictors for mortality in PsA. METHODS: The study was carried out at the University of Toronto Psoriatic Arthritis Clinic where patients are followed prospectively according to a standard protocol at 6- to 12- month intervals. Standardized mortality ratios (SMRs) were calculated overall, by age, and by sex with reference to the Ontario population. Causes of death were recorded by ICD9 and ICD10 codes and cause-specific SMRs were computed. Cox regression models were used to identify predictors for mortality among PsA patients. RESULTS: Among 1490 patients followed over 15062.8 patient-years, 225 (15%) confirmed deaths were recorded (111 females, 114 males). The overall SMR was 0.92 (95% CI: 0.81-1.05), the sex-specific SMRs were 1.08 (95% CI: 0.89-1.30) for females and 0.81 (95% CI: 0.66-0.97) for males. The age-specific SMRs were 3.36 (95% CI: 1.61-6.18), 0.97 (95% CI: 0.68-1.34), 0.88 (95% CI: 0.73-1.06) and 0.86 (95% CI: 0.66-1.11) for 20-39, 40-59, 60-79 and above 80 years of age, respectively. Major causes of death included malignant neoplasms (n=61; SMR=0.97, 95% CI: 0.72-1.28), acute myocardial infarction (n=32; SMR=1.11, 95% CI: 0.74-1.58), and pneumonia (n=14; SMR=2.46, 95% CI: 1.27-4.31). Factors found to be associated with increased mortality include elevated acute phase reactants, presence of comorbidities such as heart disease and cancer, and lower education level. CONCLUSION: Young patients with PsA are at increased mortality risk. Better control of comorbidities may reduce this risk.
BACKGROUND/ OBJECTIVES:Mortality studies in psoriatic arthritis (PsA) have provided inconsistent results. This study aimed to: 1) Estimate trends in mortality rates among PsA patients over calendar time; 2) Evaluate cause-specific mortality rates in patients with PsA compared to the general population; 3) Identify predictors for mortality in PsA. METHODS: The study was carried out at the University of Toronto Psoriatic Arthritis Clinic where patients are followed prospectively according to a standard protocol at 6- to 12- month intervals. Standardized mortality ratios (SMRs) were calculated overall, by age, and by sex with reference to the Ontario population. Causes of death were recorded by ICD9 and ICD10 codes and cause-specific SMRs were computed. Cox regression models were used to identify predictors for mortality among PsA patients. RESULTS: Among 1490 patients followed over 15062.8 patient-years, 225 (15%) confirmed deaths were recorded (111 females, 114 males). The overall SMR was 0.92 (95% CI: 0.81-1.05), the sex-specific SMRs were 1.08 (95% CI: 0.89-1.30) for females and 0.81 (95% CI: 0.66-0.97) for males. The age-specific SMRs were 3.36 (95% CI: 1.61-6.18), 0.97 (95% CI: 0.68-1.34), 0.88 (95% CI: 0.73-1.06) and 0.86 (95% CI: 0.66-1.11) for 20-39, 40-59, 60-79 and above 80 years of age, respectively. Major causes of death included malignant neoplasms (n=61; SMR=0.97, 95% CI: 0.72-1.28), acute myocardial infarction (n=32; SMR=1.11, 95% CI: 0.74-1.58), and pneumonia (n=14; SMR=2.46, 95% CI: 1.27-4.31). Factors found to be associated with increased mortality include elevated acute phase reactants, presence of comorbidities such as heart disease and cancer, and lower education level. CONCLUSION: Young patients with PsA are at increased mortality risk. Better control of comorbidities may reduce this risk.
Authors: Rubén Queiro; Daniel Seoane-Mato; Ana Laiz; Eva Galindez Agirregoikoa; Carlos Montilla; Hye Sang Park; Jose A Pinto Tasende; Juan José Bethencourt Baute; Beatriz Joven Ibáñez; Elide Toniolo; Julio Ramírez; Cristina Pruenza García-Hinojosa Journal: Front Med (Lausanne) Date: 2022-04-28
Authors: Andrew Östör; Filip Van den Bosch; Kim Papp; Cecilia Asnal; Ricardo Blanco; Jacob Aelion; Gabriela Alperovich; Wenjing Lu; Zailong Wang; Ahmed M Soliman; Ann Eldred; Lisa Barcomb; Alan Kivitz Journal: Ann Rheum Dis Date: 2021-11-23 Impact factor: 19.103
Authors: Nicola Luigi Bragazzi; Charlie Bridgewood; Abdulla Watad; Giovanni Damiani; Dennis McGonagle Journal: Front Immunol Date: 2022-04-22 Impact factor: 8.786
Authors: Philip J Mease; Atul A Deodhar; Désirée van der Heijde; Frank Behrens; Alan J Kivitz; Jeffrey Neal; Jonghyeon Kim; Shalabh Singhal; Miroslawa Nowak; Subhashis Banerjee Journal: Ann Rheum Dis Date: 2022-03-03 Impact factor: 27.973
Authors: Vasiliki-Kalliopi Bournia; George E Fragoulis; Panagiota Mitrou; Konstantinos Mathioudakis; Anastasios Tsolakidis; George Konstantonis; Georgia Vourli; Dimitrios Paraskevis; Maria G Tektonidou; Petros P Sfikakis Journal: RMD Open Date: 2021-11